BIRC7 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL22623384	0.66	5/20
SCHEMBL22623386	0.50	5/20
SCHEMBL22623382	0.48	5/20
SCHEMBL22623324	0.46	5/20
SCHEMBL22623452	0.46	5/20
SCHEMBL22623460	0.46	5/20
SCHEMBL22623316	0.64	4/20
SCHEMBL22623389	0.64	4/20
SCHEMBL22623390	0.64	4/20
SCHEMBL22623451	0.60	4/20
SCHEMBL12422146	0.58	4/20
SCHEMBL22623453	0.58	4/20
SCHEMBL22623454	0.58	4/20
SCHEMBL10081311	0.58	4/20
SCHEMBL13104601	0.58	4/20
SCHEMBL24619580	0.58	4/20
SCHEMBL12674533	0.56	4/20
SCHEMBL22623315	0.56	4/20
SCHEMBL22623455	0.54	4/20
SCHEMBL24619632	0.54	4/20

Clinical trials — most relevant to BIRC7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer	PHASE4	UNKNOWN
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma	PHASE4	UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis	PHASE2	COMPLETED
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC	PHASE2	COMPLETED
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer	PHASE2	COMPLETED
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma	PHASE2	ACTIVE_NOT_RECRUITING
Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma	PHASE1	ACTIVE_NOT_RECRUITING
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma	PHASE1	COMPLETED
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma	PHASE1	COMPLETED
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer	PHASE1	COMPLETED
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma	PHASE1	ACTIVE_NOT_RECRUITING
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage	nan	COMPLETED
Dietary Intervention With High Phenolic EVOO in CLL	nan	COMPLETED
Molecular Mechanism of Nasopharyngeal Carcinoma	nan	UNKNOWN
Autophagy Bladder Cancer	nan	UNKNOWN
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases	nan	UNKNOWN
MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA	nan	UNKNOWN
Circulating Markers for Ischemic Heart Disease	nan	RECRUITING
Apoptosis Markers in Aggressive Periodontitis	nan	COMPLETED
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient	nan	RECRUITING
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure	nan	RECRUITING
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Inflammasomes in Cell Death in FTMH, ERM, and RRD	nan	COMPLETED
Impact of CASP3 Gene in Chemoresistance	nan	NOT_YET_RECRUITING
Role of Vaspin in Pathophysiology of Pre-eclampsia	nan	UNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
The Effect of TRA-8 on Ovarian Cancer Tissue	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a BIRC7 binder may also engage these)

Protein	Name	Similarity
A2AWP0	—	0.989	A2AWP0 →
O94761	—	0.979	O94761 →
Q5RA67	—	0.973	Q5RA67 →
TESK1	Dual specificity testis-specific protein kinase 1	0.973	landscape →
Q63572	—	0.972	Q63572 →
Q9Y6S9	—	0.971	Q9Y6S9 →
O43918	—	0.971	O43918 →
Q2LGB3	—	0.971	Q2LGB3 →
Q75NR7	—	0.971	Q75NR7 →
Q8CIE4	—	0.970	Q8CIE4 →
Q96AC6	—	0.970	Q96AC6 →
A9ULZ2	—	0.969	A9ULZ2 →
Q7Z6P3	—	0.969	Q7Z6P3 →
Q5VTJ3	—	0.969	Q5VTJ3 →
Q2TBC4	—	0.969	Q2TBC4 →
Q8R2S1	—	0.969	Q8R2S1 →
Q9Z0E3	—	0.969	Q9Z0E3 →
Q8BWA8	—	0.969	Q8BWA8 →
Q8BLR5	—	0.969	Q8BLR5 →
Q8IW93	—	0.968	Q8IW93 →
Q8K330	—	0.968	Q8K330 →
Q96PX9	—	0.968	Q96PX9 →
Q8NDX1	—	0.968	Q8NDX1 →
Q90ZZ6	—	0.968	Q90ZZ6 →
A0A8I3PMN2	—	0.968	A0A8I3PMN2 →
Q5FWH6	—	0.968	Q5FWH6 →
Q811H0	—	0.967	Q811H0 →
Q5XIS1	—	0.967	Q5XIS1 →
Q9NWS9	—	0.967	Q9NWS9 →
A2APT9	—	0.967	A2APT9 →